Overview

A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas

Status:
Completed

Trial end date:
2012-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the maximum tolerated dose (MTD) of BMS-833923 administered in combination with Cisplatin and Capecitabine as first-line therapy in subjects with inoperable metastatic gastric, gastroesophageal or esophageal adenocarcinomas.

Phase:

Phase 1

Details

Lead Sponsor:

Bristol-Myers Squibb

Collaborator:

Exelixis

Treatments:

Capecitabine
Cisplatin